Compare Regeneron Pharmaceuticals Inc (REGN) vs Uber Technologies Inc (UBER) Price & Performance

Regeneron Pharmaceuticals (REGN) trades at $739.57, up 0.12% on the day, with a bearish technical signal but strong fundamental performance. Recent earnings have consistently beaten estimates, and the company maintains robust profitability with a net income margin of 27.86%. A major $8 billion expansion of the immunology alliance with Sanofi, announced October 1, 2026, provides significant future revenue potential and strategic momentum.

The outlook is positive, supported by strong earnings, a lucrative partnership, and a consensus analyst price target of $846. Key risks include competitive pressures in key drug markets and reliance on successful clinical trial outcomes. The stock presents a compelling opportunity for growth investors, though volatility may persist near-term.

Uber (UBER) trades at $70.24, up 1.68% on the day, with a bearish technical signal from moving averages but strong fundamentals including 2025 revenue of $52.02 billion and net income of $10.05 billion. The company has beaten EPS estimates in two of the last three quarters and expanded its Uber Eats partnership with Costco to 47 states as of September 16, 2026. Operating cash flow grew to $10.10 billion in 2025, supporting a robust balance sheet with $6.98 billion in cash.

The outlook is positive given analyst consensus of a $104.72 price target and 82.54% buy ratings, though risks include a projected negative net cash flow in 2026 and competitive pressures from autonomous vehicle entrants. Upside is driven by earnings momentum and strategic expansions, while investor caution is warranted on execution and capital expenditure trends.